As the world is struggling to emerge out ofpandemic, a good news came in late Tuesday evening of Italy claiming to have the world’s first COVID-19 vaccine.
Reportedly the tests which were carried out at infectious disease of Rome, Spallanzani Hospital have helped in development of antibodies in mice which are also reportedly working on human cells.
Luigi Aurisicchio, CEO of Takis, company developing the medication told the Italian news agency ANSA that this vaccine is in the most advanced stage of candidate testing and that the human tests are expected to commence late summer.
The scientists in Spallanzani Hospital tested the vaccine on mice and have stated that the mice developed antibodies against virus after first dose which is blocking virus from infecting the human cells.
Five vaccine candidates are developed and two are selected for further testing and observation based on ‘genetic material of DNA spike.’
Pharma moguls and nations have already started work on the vaccine development, but it is still a long way to go. With COVID -19 vaccine hunt heating up across the globe, there is still no concrete estimate as to when we will have vaccine ready to be supplied.
On Tuesday, Pfizer Inc and BioNTech stated that they have started the delivery of experimental coronavirus vaccine for human trials in the United States.
Furthermore, Oxford University said that they are teaming up with AstraZeneca to produce COVID-19 vaccine which will hopefully be ready by the end of this year.
The rapid spread of the COVID-19 virus globally in a short span of time with no concrete knowledge regarding the true nature of this virus is posing to be the biggest challenge in development of vaccine for the SARS-CoV-2 virus.
It should be understood that vaccine development is a long process which takes years and has high risks of failure.
According to Milken Institute, USA, there are potential 111 vaccines in the course of development across the globe. Out of these nine are under initial clinical trials while the rest are in pre-clinical trial phase.
Post the vaccine development what will determine our control over the virus spread will be the scale of vaccine production, it’s distribution to all countries including the poor and developing nations.